Skip to main content
SpringerLink
Log in

Neuromotor Dysfunction in Early Psychosis

  • Published:
Annals of Clinical Psychiatry

Abstract

Neuromotor dysfunction, particularly extrapyramidal signs and symptoms (EPSS), plays an important role in the assessment and treatment of patients in the early stages of psychotic disorders such as schizophrenia. By blocking dopamine D2 receptors, antipsychotic medications can produce EPSS, including tardive dyskinesia. EPSS is also observed in a third or more of patients first presenting with a psychotic disorder, prior to initiation of antipsychotic pharmacotherapy. This suggests that abnormalities in neuromotor control may be an integral component of the brain mechanisms associated with psychosis. Atypical antipsychotic agents can alleviate psychosis without inducing EPSS. Preexisting EPSS may be corrected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Kraepelin E: Dementia Praecox and Paraphrenia:Edinburgh: E & S Livingstone; 1919

    Google Scholar 

  2. Taber's Cyclopedic Medical Dictionary. Philadelphia, PA: Davis; 1981

  3. McEvoy JP, Freter S: The dose-response relationship formemory impairment by anticholinergic drugs. Compr Psychiatry 1989; 30:135–138

    Google Scholar 

  4. Stip E: Memory impairment in schizophrenia: Perspectives from psychopathology and pharmacotherapy. Can J Psychiatry 1996; 41(8, Suppl 2):S27-S34

    Google Scholar 

  5. Jeste DV, Caligiuri MP: Tardive dyskinesia. Schizophr Bull 1993; 19:303–315

    Google Scholar 

  6. de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J: Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000; 157:1019–1020

    Google Scholar 

  7. Weiden PJ, Mann JJ, Dixon L, Haas G, DeChillo N, Frances AJ: Is neuroleptic dysphoria a healthy response? Compr Psychiatry 1989; 30:546–552

    Google Scholar 

  8. Awad AG, Voruganti LN, Heslegrave RJ, Hogan TP: Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome. Int Clin Psychopharmacol 1996; 11(Suppl 2):55–59

    Google Scholar 

  9. Barbosa ER, Limongi JC, Cummings JL: Parkinson's disease. Psychiatr Clin N Am 1997; 20:769–790

    Google Scholar 

  10. Haddad MS, Cummings JL: Huntington's disease. Psychiatr Clin N Am 1997; 20:791–807

    Google Scholar 

  11. Wichmann T, DeLong MR: Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg Clin N Am 1998; 9:223–236

    Google Scholar 

  12. Munetz MR, Benjamin S: How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39:1172–1177

    Google Scholar 

  13. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672–676

    Google Scholar 

  14. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11–19

    Google Scholar 

  15. Chouindard G, Ross-Chouinard A, Annable L, Jones BD: Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7:233

    Google Scholar 

  16. Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): A structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res 1989; 27:335–350

    Google Scholar 

  17. Sanders RD, Forman SD, Pierri JN, Baker RW, Kelley ME, Van Kammen DP, Keshavan MS: Inter-rater reliability of the neurological examination in schizophrenia. Schizophr Res 1998; 29:287–292

    Google Scholar 

  18. Haase HJ: Dosierung der Neuroleptika. Erlangen: Perimed; 1983:39–55

    Google Scholar 

  19. Kuenstler U, Muller-Oerlinghausen B: The handwriting test as an aid to neuroleptic dosage. Int J Clin Pharmacol Ther Toxicol 1985; 23(Suppl 1):S34-S41

    Google Scholar 

  20. Kuenstler U, Juhnhold U, Knapp WH, Gertz HJ: Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. Psychiatry Res 1999; 90:31–39

    Google Scholar 

  21. Stip E: Novel antipsychotics: Issues and controversies. Typicality of atypical antipsychotics. J Psychiatry Neurosci 2000; 25:137–153

    Google Scholar 

  22. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43:135–145

    Google Scholar 

  23. Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153:466–476

    Google Scholar 

  24. Kapur S, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514–520

    Google Scholar 

  25. McEvoy JP, Stiller RL, Farr R: Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. J Clin Psychopharmacol 1986; 6:133–138

    Google Scholar 

  26. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739–745

    Google Scholar 

  27. Kapur S, Zipursky RB, Remington G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286–293

    Google Scholar 

  28. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia:Apreliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57:553–559

    Google Scholar 

  29. Kapur S, Seeman P: Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001; 158:360–369

    Google Scholar 

  30. Seeman P: Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; 47:27–38

    Google Scholar 

  31. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S: 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 1998; 15:921–928

    Google Scholar 

  32. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825–835

    Google Scholar 

  33. Simpson GM, Lindenmayer JP: Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17:194–201

    Google Scholar 

  34. Kopala LC: Clinical experience in developing treatment regimens with the novel antipsychotic risperidone. Int Clin Psychopharmacol 1997; 12(Suppl 4):S11-S18

    Google Scholar 

  35. Casey DE: Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998; 59(Suppl 3):31–37

    Google Scholar 

  36. Glazer WM: Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61(Suppl 3):16–21

    Google Scholar 

  37. Barnes TR, McPhillips MA: Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13(Suppl 3):S49-S57

    Google Scholar 

  38. Collaborative Working Group on Clinical Trial Evaluations: Assessment of EPSS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998; 59(Suppl 12):23–27

    Google Scholar 

  39. Carlsson A, Waters N, Carlsson ML: Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 1999; 46:1388–1395

    Google Scholar 

  40. Kopala LC: Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand Suppl 1996; 389:12–17

    Google Scholar 

  41. Caligiuri MP, Lohr JB, Jeste DV: Parkinsonism in neurolepticnaïve schizophrenic patients. Am J Psychiatry 1993; 150(9): 1343–1348

    Google Scholar 

  42. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane JM, Alvir J, Lieberman JA: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995; 152:1724–1729

    Google Scholar 

  43. Fenton WS, Wyatt RJ, McGlashan TH: Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994; 51:643–650

    Google Scholar 

  44. Kopala LC, Good KP, Honer WG: Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone. J Clin Psychopharmacol 1997; 17:308–313

    Google Scholar 

  45. Kopala L, Good K, Fredrikson D, Whitehorn D, Lazier L, Honer W: Risperidone in first-episode schizophrenia: Improvement in symptoms and pre-existing extrapyramidal signs. Int J Psychiatr Clin Pract 1998; 2(Suppl):S19-S25

    Google Scholar 

  46. Lang DJ, Kopala LC, Vandorpe RA, Smith GN, Riu Q, Goghari VM, Honer WG: Basal ganglia volumes and treatment-response in never-medicated, first-episode schizophrenia patients. Schizophrenia Research 2001; 49:159

    Google Scholar 

  47. Keshavan MS, Rosenberg D, Sweeney JA, Pettegrew JW: Decreased caudate volume in neuroleptic-naïve psychotic patients. Am J Psychiatry 1998; 155:774–778

    Google Scholar 

  48. Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, Honer WG: An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am J Psychiatry 2001; 158:625–631

    Google Scholar 

  49. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC: Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics. Am J Psychiatry 1999; 156:1200–1204

    Google Scholar 

  50. Busatto GF, Kerwin RW: Schizophrenia, psychosis, and the basal ganglia. Psychiatr Clin N Am 1997; 20:897–910

    Google Scholar 

  51. Graybiel AM: The basal ganglia and cognitive pattern generators. Schizophr Bull 1997; 23:459–469

    Google Scholar 

  52. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321–330

    Google Scholar 

  53. Menon V, Anagnoson RT, Glover GH, Pfefferbaum A: Functional magnetic resonance imaging evidence for disrupted basal ganglia function in schizophrenia. Am J Psychiatry 2001; 158:646–649

    Google Scholar 

  54. Andreasen NC, Paradiso S, O'Leary DS: "Cognitive dysmetria" as an integrative theory of schizophrenia: A dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr Bull 1998; 24:203–218

    Google Scholar 

  55. Crespo-Facorro B, Paradiso S, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD: Recalling word lists reveals "cognitive dysmetria" in schizophrenia: A positron emission tomography study. Am J Psychiatry 1999; 156:386–392

    Google Scholar 

  56. Liddle PF, Lane CJ, Ngan ET: Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. Br J Psychiatry 2000; 177:402–407

    Google Scholar 

  57. Australian Clinical Guidelines for Early Psychosis: National Early Psychosis Program. Melbourne, Australia; 1998

  58. The Canadian Psychiatric Association: Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998; 43(Suppl 2):25S-40S

    Google Scholar 

  59. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(Suppl 4):1–63

    Google Scholar 

  60. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush J, Shon SP: The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999; 60:649–657

    Google Scholar 

  61. Fitzgerald PB, Kapur S, Caligiuri MP, Jones C, Silvestri S, Remington G, Zipursky RB: Instrumentally detected changes in motor functioning in patients with low levels of antipsychotic dopamine D2 blockade. Neuropsychopharmacology 2000; 22:19–26

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nova Scotia Early Psychosis Program, Dartmouth, Nova Scotia, Canada

    David Whitehorn

  2. Dalhousie University, Halifax, Canada

    David Whitehorn & Lili C. Kopala

Authors
  1. David Whitehorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lili C. Kopala
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whitehorn, D., Kopala, L.C. Neuromotor Dysfunction in Early Psychosis. Ann Clin Psychiatry 14, 113–121 (2002). https://doi.org/10.1023/A:1016859005849

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016859005849

Search

Navigation